2 completed, 1 withdrawn. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
Follow Hyperactive Delirium: new trials by email Literature Review of Hyperactive Delirium trials Research Report on Hyperactive Delirium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phenobarbital for Agitated Delirium Phenobarbital, Conventional therapy group - Agitated Delirium, Delirium Confusional State | Phase 3 | Withdrawn | Duke University | 2026-06-01 | 2026-11-06 | |
| Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium Quatiapine, Haloperidol - Hyperactive Delirium | Phase 3 | Completed | Alexandria University | 100 | 2023-04-09 | 2023-08-30 |
| HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial Haldol 2mg/ml oral solution, Olanzapine Actavis 5mg orodispersible tablet - Haloperidol, Advanced Cancer | Phase 3 | Completed | Tan Tock Seng Hospital | 22 | 2022-05-18 | 2026-10-05 |
Confusion (1)
Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Haloperidol (2) · Phenobarbital (1) · Solutions (1)
Alexandria University (1) · Duke University (1) · Tan Tock Seng Hospital (1)
Egypt (1) · Singapore (1) · United States (1)
Ibrahim K. Luttfi, PHD (1) · Islam E. Ahmed, PharmD (1) · Keith W. Van Dusen, M.D. (1) · Mervyn Koh (1) · Tamer N. Habib, MD (1)